Super-Sizing A Cancer Drug Minimizes Side Effects, Harvard University And Massachusetts Institute of Technology (MIT) Study

ClinicaSpace Login

Enter your ClinicaSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

Clinical Research
News & Careers

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
FREE Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Date
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Today's Hot Jobs
Most Recent Jobs
Search Jobs
Post Resume
Career Resources
For Employers

COMMUNITY
Login
Become a Member
FAQ

PROFILES
Company Profiles

INDUSTRY EVENTS
Clinical

RESOURCES
Real Estate
New Business Opportunities

News | News By Subject | News By Date | Search News

Email

Super-Sizing A Cancer Drug Minimizes Side Effects, Harvard University And Massachusetts Institute of Technology (MIT) Study
7/30/2010

Physorg -- One of the first chemotherapy drugs given to patients diagnosed with cancer — especially lung, ovarian or breast cancer — is cisplatin, a platinum-containing compound that gums up tumor cells’ DNA. Cisplatin does a good job of killing those tumor cells, but it can also seriously damage the kidneys, which receive high doses of cisplatin because they filter the blood.

Read at Physorg.com

Read at News Release

Read Article at

Related Companies

News Categories

• Physorg.com

• News Release

• Harvard University

• Massachusetts Institute of Technology (MIT)

• Academic - Research

• Clinical - Research